EP12.03. Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib. - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Leonardo Rojas
Meta Tag
Speaker Leonardo Rojas
Topic Metastatic NSCLC: Targeted Therapy - Other
TP53 mutations
Hispanic patients
EGFR-positive NSCLC
molecular profiling
clinicopathological features
tumor mutational burden
overall response rate
progression-free survival
overall survival
Powered By